XFOR
X4 Pharmaceuticals Inc
2.90$
+2.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 85.3% | 82.9% | 77.8% | 83.3% | 80.2% | 76.6% | 73.6% | 69.4% | 81.2% | 90.1% | 89.5% | 86.5% | |
| 76.1% | 67.5% | 53.9% | 69.9% | 54.7% | 38.0% | 31.0% | 37.3% | 42.6% | 74.7% | 80.3% | 77.1% | |
| 81.9% | 77.7% | 72.1% | 80.1% | 75.8% | 69.7% | 66.9% | 59.9% | 74.7% | 87.1% | 86.5% | 82.2% | |
| 0.2% | 0.4% | 0.6% | 0.4% | 0.6% | 1.2% | 0.9% | 1.8% | 1.0% | 0.2% | 0.4% | 0.8% | |
| – | 0.0% | – | 0.4% | 1.4% | 1.9% | 2.4% | 3.0% | 2.5% | 1.5% | 1.7% | 2.2% | |
| 10.0% | 11.8% | 15.5% | 8.2% | 9.7% | 11.8% | 13.3% | 16.5% | 10.6% | 6.0% | 6.4% | 6.9% | |
| – | – | – | 4.9% | 5.7% | 6.8% | 7.5% | 9.2% | 5.8% | 3.2% | 3.4% | 5.2% | |
| 61.0% | 65.3% | 99.1% | 55.2% | 66.5% | 84.9% | 82.4% | 96.2% | 62.3% | 35.9% | 37.7% | 38.6% | |
| 14.7% | 15.5% | 21.0% | 13.7% | 16.4% | 22.4% | 19.9% | 21.8% | 14.4% | 8.9% | 8.8% | 7.7% | |
| 0.6% | 0.7% | 1.0% | 0.6% | 0.7% | 0.9% | 1.0% | 1.3% | 0.7% | 0.3% | 0.3% | 0.2% | |
| 4.7% | 6.1% | 8.0% | 3.8% | 4.8% | 5.9% | 8.5% | 7.3% | 3.1% | 2.0% | 1.9% | 1.6% | |
| 31.3% | 37.1% | 48.9% | 35.6% | 42.2% | 51.5% | 58.2% | 72.1% | 46.5% | 26.3% | 28.3% | 30.3% | |
| 39.0% | 34.7% | 0.9% | 44.8% | 33.5% | 15.1% | 17.6% | 3.8% | 37.7% | 64.1% | 62.3% | 61.4% | |
| -264.7% | -324.5% | -472.2% | -208.4% | -266.9% | -351.9% | -396.2% | -514.2% | -348.9% | -204.7% | -227.5% | -249.3% | |
| 3.8% | 4.5% | 5.9% | 3.2% | 3.8% | 4.6% | 5.3% | 7.0% | 26.5% | 38.1% | 46.7% | 49.9% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.